Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma

Background: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been approved. Sorafenib is an oral multikinase inhibitor approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Yasuhiro, Onoda, Naoyoshi, Ito, Ken-ichi, Sugitani, Iwao, Takahashi, Shunji, Yamaguchi, Iku, Kabu, Koki, Tsukada, Katsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mary Ann Liebert, Inc. 2017
Materias:
Thyroid Cancer and Nodules
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646744/
https://www.ncbi.nlm.nih.gov/pubmed/28635560
http://dx.doi.org/10.1089/thy.2016.0621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5646744/
https://www.ncbi.nlm.nih.gov/pubmed/28635560
http://dx.doi.org/10.1089/thy.2016.0621

Ejemplares similares